Quantum Healthcare Limited – Fourth Annual General Meeting (2026): Key Investor Takeaways
Date of AGM: 30 April 2026
Location: 133 New Bridge Road, Chinatown Point, #21-06, Singapore 059413
1. Introduction and Board Attendance
The Fourth Annual General Meeting (AGM) of Quantum Healthcare Limited was convened with full attendance by the Board of Directors and the Chief Financial Officer. The meeting was chaired by Mr. Ng Fook Ai Victor (Independent Chairman). Other key directors present included Dr. Gian Siong Lin Jimmy (CEO & Executive Director), Mr. Ross Yu Limjoco, and Mr. Chong Eng Wee (both Independent Directors).
2. Meeting Procedures and Voting
The AGM was conducted in accordance with the Company’s constitution and Singapore Exchange (SGX) Catalist Rules. All resolutions were subjected to a poll vote, with Moore Stephens LLP appointed as independent scrutineer and Complete Corporate Service Pte. Ltd. as polling agent. Notably, no shareholder questions were submitted prior to or during the AGM.
3. Adoption of Financial Statements
Unanimous approval was granted to the Directors’ Statement and Audited Financial Statements for the financial year ended 31 December 2025, along with the Independent Auditor’s Report. Investors should note the absence of any dissenting votes, suggesting broad shareholder confidence in the company’s financial stewardship for FY2025.
4. Board Re-Elections
- Dr. Gian Siong Lin Jimmy was re-elected as Director (appointed 13 February 2026).
- Mr. Ross Yu Limjoco was re-elected as Director (appointed 23 February 2026).
- Mr. Chong Eng Wee was re-elected as Director (appointed 2 March 2026).
All re-elections were approved unanimously. The current Board structure and leadership remain unchanged, indicating continued strategic direction and stability.
5. Director Fees
Shareholders approved the payment of Directors’ fees totaling S\$145,000 for the financial year ending 31 December 2026, to be paid quarterly in arrears. This is consistent with the prior year, suggesting no increase in Board compensation.
6. Re-Appointment of Auditors
Forvis Mazars LLP was re-appointed as the Company’s auditors for the coming financial year. Directors were authorized to fix their remuneration. The re-appointment of a reputable audit firm may reassure investors regarding the integrity of Quantum Healthcare’s financial reporting.
7. Share Issue Mandate
Shareholders granted the Board authority to allot and issue new shares pursuant to Section 161 of the Companies Act and Rule 806 of the Catalist Rules. The mandate allows for the potential issuance of up to 100% of total issued shares, with a cap of 50% for non-pro-rata issues. This authority remains until the next AGM.
- Potential for share dilution exists if the Board exercises this mandate. However, it also provides strategic flexibility for capital raising, future M&A, or incentive programs.
- Investors should monitor any subsequent announcements regarding share placements or rights issues, as such actions could impact share price and ownership dilution.
8. Renewal of Share Buy-Back Mandate
The AGM approved the renewal of the Share Buy-Back Mandate, allowing the Company to repurchase up to 10% of its issued shares (excluding treasury shares and subsidiary holdings) on-market (at up to 105% of the average closing price) or off-market (at up to 120% of the average closing price). This mandate remains valid until the next AGM or until it is revoked.
- Share buy-backs can provide price support and signal management confidence in the company’s valuation. However, this also reduces cash reserves and may impact future investment capacity.
- Investors should watch for any actual buy-back activity, which could be price sensitive and affect the share value.
9. Other Matters
There were no other items of business or shareholder questions. The meeting concluded promptly, with the Chairman affirming that the minutes will be published on SGXNet and the Company’s website within one month.
Key Takeaways for Investors
- Stable Board composition and leadership, with unanimous support for all resolutions.
- Potential for share issuance and buy-backs in the coming year, which could be price sensitive depending on how these mandates are utilized.
- No increase in Director fees; financial statements and auditors re-appointed with full shareholder support.
- No current news of significant transactions, acquisitions, or operational changes.
Potential Price-Sensitive Issues
- The renewed share issue mandate and buy-back authority provide the Board with significant flexibility. Any substantial exercise—whether for capital raising or share repurchases—could have a material impact on share price due to dilution or market support effects.
- Investors are advised to monitor future SGX announcements closely for developments regarding share placements, buy-backs, or other corporate actions.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information herein is based on official company minutes and may not reflect subsequent developments.
量子医疗有限公司 – 2026年第四届年度股东大会：投资者需知要点
股东大会日期：2026年4月30日
地点：133 New Bridge Road, Chinatown Point, #21-06, Singapore 059413
1. 简介及董事会出席情况
量子医疗有限公司第四届年度股东大会（AGM）顺利召开，董事会全体成员及首席财务官出席。会议由独立主席Ng Fook Ai Victor先生主持，其他主要董事包括CEO兼执行董事Dr. Gian Siong Lin Jimmy、独立董事Ross Yu Limjoco先生和Chong Eng Wee先生。
2. 会议流程与投票方式
会议依照公司章程及新交所Catalist规则进行。所有决议案以投票方式表决，由Moore Stephens LLP担任独立计票员，Complete Corporate Service Pte. Ltd.为投票代理。值得注意的是，会前及会中均无股东提交问题。
3. 财务报表通过
与会股东全票通过了2025年12月31日止财务年度的董事声明及经审计财务报表，以及独立审计师报告。 无反对票表明股东对公司财务管理非常信任。
4. 董事会重选
- Dr. Gian Siong Lin Jimmy（2026年2月13日任命）成功连任董事。
- Mr. Ross Yu Limjoco（2026年2月23日任命）成功连任董事。
- Mr. Chong Eng Wee（2026年3月2日任命）成功连任董事。
所有董事重选均获全票通过。 这意味着董事会结构和公司战略方向保持稳定。
5. 董事酬金
股东批准支付2026财年董事酬金145,000新元，按季度结算，与去年持平。
6. 审计师续任
Forvis Mazars LLP继续担任公司审计师，董事有权决定其报酬。知名审计机构的续任有助于提升公司财报公信力。
7. 配股授权
股东授权董事会可根据公司法第161条及Catalist规则第806条发行新股，发行总量上限为已发行股份的100%，非按比例发行上限为50%。授权有效期至下届股东大会。
- 新股发行或将导致股权稀释，但也赋予公司灵活筹资或进行并购/激励计划的能力。
- 投资者应密切关注后续有关配股、私募或其他融资公告，这类动作可能影响股价和持股结构。
8. 股份回购授权续期
会议通过续期股份回购授权，允许公司回购不超过已发行股份10%（不包括库存股及子公司持股），市场回购上限为平均收盘价的105%，场外回购为120%。该授权有效期至下届股东大会或被撤销。
- 股份回购可支撑公司股价，彰显管理层对公司价值有信心，但也会减少现金储备，对未来投资能力产生影响。
- 投资者应关注公司是否实际启动回购，这将对股价产生敏感影响。
9. 其他事项
无其他业务或股东提问。会议准时结束，主席承诺会后一个月内在SGXNet和公司官网发布会议纪要。
投资者需关注的重点
- 董事会结构稳定，所有决议全票通过。
- 公司有灵活发行新股及回购股份的权力，后续动态可能影响股价。
- 董事酬金无增加，财报及审计师续任获得全体支持。
- 暂无重大并购、业务调整或其他实质性新闻。
潜在价格敏感因素
- 配股及回购授权赋予公司极大操作空间，若大规模执行，或将对公司估值和股价带来重大影响。
- 投资者应密切关注公司后续在新交所发布的相关公告。
免责声明
本文内容仅供参考，不构成投资建议。投资者应自行尽职调查，并咨询专业顾问后再做决策。本文信息基于公司官方会议纪要，可能未能涵盖会后最新动态。
